Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

Cephalon

Status and phase: Completed; Phase 3

Conditions: General Anxiety Disorder

Treatments: Drug: GABITRIL (tiagabine hydrochloride; CEP-6671)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00233675

C6671A/301/AX/US

Details and patient eligibility

About

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Not available at time of registration

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)